Testosterone Undecylate
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05081193CT.gov Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03734653CT.gov Testosterone Therapy in Castration Resistant Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Undecylate (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | B · 61 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Testosterone Undecylate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadotropic Hypogonadism | — | P4 | A · 82 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 73 |
| Sexual Disorder | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Undecylate in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-undecylate-castration-resistant-prostate-carcinoma-90408
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →